Conformal postoperative radiotherapy in patients with positive resection margins and/or pT3-4 prostate adenocarcinoma

International Journal of Radiation Oncology, Biology, Physics
Rita BellavitaCynthia Aristei

Abstract

To evaluate outcome and toxicity of high-dose conformal radiotherapy (RT) after radical prostatectomy. Between August 1998 and December 2007, 182 consecutive patients with positive resection margins and/or pT3-4, node-negative prostate adenocarcinoma underwent postoperative conformal RT. The prescribed median dose to the prostate/seminal vesicle bed was 66.6 Gy (range 50-70). Hormone therapy (a luteinizing hormone-releasing hormone analogue and/or antiandrogen) was administered to 110/182 (60.5%) patients with high-risk features. Biochemical relapse was defined as an increase of more than 0.2 ng/mL over the lowest postoperative prostate-specific antigen (PSA) value measured on 3 occasions, each at least 2 weeks apart. Median follow-up was 55.6 months (range 7.6-141.9 months). The 3- and 5-year probability of biochemical relapse-free survival were 87% and 81%, respectively. In univariate analysis, more advanced T stages, preoperative PSA values ≥10 ng/mL, and RT doses <70 Gy were significant factors for biochemical relapse. Pre-RT PSA values >0.2 ng/mL were significant for distant metastases. In multivariate analysis, risk factors for biochemical relapse were higher preoperative and pre-RT PSA values, hormone therapy for under 4...Continue Reading

References

Mar 30, 1995·International Journal of Radiation Oncology, Biology, Physics·J D CoxT F Pajak
Oct 6, 1997·International Journal of Radiation Oncology, Biology, Physics·M J ZelefskyS A Leibel
Jul 4, 1998·International Journal of Radiation Oncology, Biology, Physics·S M EulauS L Hancock
Nov 7, 1998·International Journal of Radiation Oncology, Biology, Physics·R K ValicentiB W Corn
Jun 14, 2002·International Journal of Radiation Oncology, Biology, Physics·Zbigniew PetrovichDonald G Skinner
Jun 9, 2004·International Journal of Radiation Oncology, Biology, Physics·Cesare CozzariniEugenio Villa
Feb 15, 2005·International Journal of Radiation Oncology, Biology, Physics·Carlos VargasAlvaro A Martinez
Aug 16, 2005·Lancet·Michel BollaUNKNOWN European Organization for Research and Treatment of Cancer
Nov 16, 2006·JAMA : the Journal of the American Medical Association·Ian M ThompsonE David Crawford
Apr 28, 2009·International Journal of Radiation Oncology, Biology, Physics·Jeff M MichalskiCynthia Ménard
Jan 29, 2011·American Journal of Clinical Oncology·Carl J RossiGregory Merrick

❮ Previous
Next ❯

Citations

Sep 14, 2014·International Journal of Radiation Oncology, Biology, Physics·Sonja KatayamaKlaus Herfarth
Jul 25, 2018·Prostate Cancer and Prostatic Diseases·Giovanna MantiniAlessio G Morganti
Jul 1, 2020·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·G FrancoliniG Ingrosso
Dec 7, 2016·Reports of Practical Oncology and Radiotherapy : Journal of Greatpoland Cancer Center in Poznań and Polish Society of Radiation Oncology·Gianluca IngrossoRiccardo Santoni

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.